Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer with ALK Translocation. (12th February 2020)

• Record Type: Journal Article
• Authors: Patel, Sandip Pravin; Pakkala, Suchita; Pennell, Nathan A.; Reckamp, Karen L.; Lanzalone, Silvana; Polli, Anna; Tarazi, Jamal; Robert‐Vizcarrondo, Francisco
• Is Part Of: Oncologist. Volume 25:Number 7(2020)
• Page Start: 562
• Page End: e1012
• Publication Date: 2020-02-12
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2020-0034
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Lessons Learned : This study evaluating first‐line crizotinib plus pembrolizumab in patients with anaplastic lymphoma kinase (ALK)–positive advanced non‐small cell lung cancer (NSCLC) was terminated early because increased availability of second‐generation ALK inhibitors resulted in difficulty identifying and accruing eligible patients. In the small number of patients enrolled, elevated transaminases were the most common treatment‐related toxicity. No other relevant toxicities were observed. Although no definitive conclusions could be drawn because of the small number of patients studied, the higher frequency of severe transaminase increases noted in this sample should be of concern if ALK inhibitor and PD‐L1/PD‐1 inhibitor combinations are tested in future studies. Background: Previous research suggests single‐agent crizotinib is efficacious for the treatment of anaplastic lymphoma kinase ( ALK )–rearranged advanced non‐small cell lung cancer (NSCLC). Methods: This study evaluated the safety and preliminary antitumor activity of crizotinib plus pembrolizumab as first‐line therapy in patients with ALK ‐rearranged NSCLC. Patients were initially treated at dose level 0 (DL0) with crizotinib 250 mg twice daily and pembrolizumab 200 mg every 3 weeks (cycle duration was 3 weeks). If a dose‐limiting toxicity occurred, subsequent patients were enrolled at a lower dose level (dose level −1 [DL−1]: 3 weeks of crizotinib monotherapy 250 mg twice daily, followed by crizotinib 250 mg twice daily with the addition of pembrolizumab 200 mg every 3 weeks). The primary endpoint was dose‐limiting toxicity. Antitumor activity was assessed. Results: Nine patients were enrolled: two at DL0, then seven at DL−1. Dose‐limiting toxicities occurred in four patients (grade 3 increases in alanine aminotransferase [ALT] and aspartate aminotransferase [AST] and grade 3 fatigue at DL0; grade 3 increase in ALT and grade 3 increases in both ALT and AST at DL−1). Conclusion: The maximum tolerated dose was not determined because slow accrual resulted in early study termination.